Nanogen earns patents for use of biomarkers related to diabetes and Alzheimers Disease.Nanogen, Inc. (San Diego, CA), developer of advanced diagnostic products, has been issued six patents by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property for inventions related to diabetes and Alzheimers disease and biomarkers. United States Patent 7,052, 849, "Protein biopolymer bi·o·pol·y·mer n. A macromolecule, such as a protein or nucleic acid, that is formed in a living organism. biopolymer any protein or nucleic acid produced by a living organism. markers predictive of insulin resistance Insulin Resistance Definition Insulin resistance is not a disease as such but rather a state or condition in which a person's body tissues have a lowered level of response to insulin, a hormone secreted by the pancreas that helps to regulate the level ," United States Patent 7, 049,397, "Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons," and United States Patent 7,087,435, "Biopolymer marker indicative of disease state having a molecular weight of 2735 daltons," relate to the use of mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. and time-of-flight detection to identify various biomarkers such as those associated with metabolic Syndrome X and conditions linked to Syndrome X. Early stages of Syndrome X are characterized by insulin resistance, abnormal blood lipids and high blood pressure; later stages lead to overt diabetes, kidney failure and heart failure. In addition, United States Patent 7,026,129 "IG lambda biopolymer markers predictive of Alzheimers disease," and United States Patent 7,074,576, "Protein biopolymer markers indicative of Alzheimers disease," relate to the utilization of mass spectrometry and time-of-flight detection measures to elucidate biopolymer markers associated with Alzheimers disease and Syndrome X. United States Patent 7,070,945, "Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment mild cognitive impairment (MCI), n memory loss generally associated with aging; does not affect normal independent functioning of an individual. ," claims a method for determining those patients suffering from mild cognitive impairment who have a likelihood of progressing to Alzheimers disease. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, by immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. of bodily fluids. In addition, a method for distinguishing between AD and non-AD dementia is disclosed. Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) reagents, the NanoChip electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization min·i·a·tur·ize tr.v. min·i·a·tur·ized, min·i·a·tur·iz·ing, min·i·a·tur·iz·es To plan or make on a greatly reduced scale. min and continues to be supported for its potential for diagnostic and biodefense applications. Nanogen, Inc. +1-858-410-4600 www.nanogen.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion